Literature DB >> 15537754

Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain.

Rachel Lowe1, Dean L Pountney, Poul Henning Jensen, Wei Ping Gai, Nicolas H Voelcker.   

Abstract

Alpha-synuclein filaments are the major component of intracytoplasmic inclusion bodies characteristic of Parkinson's disease and related disorders. The process of alpha-synuclein filament formation proceeds via intermediate or protofibrillar species, each of which may be cytotoxic. Because high levels of calcium(II) and other metal ions may play a role in disease pathogenesis, we investigated the influence of calcium and other metals on alpha-synuclein speciation. Here we report that calcium(II) and cobalt(II) selectively induce the rapid formation of discrete annular alpha-synuclein oligomeric species. We used atomic force microscopy to monitor the aggregation state of alpha-synuclein after 1 d at 4 degrees C in the presence of a range of metal ions compared with the filament formation pathway in the absence of metal ions. Three classes of effect were observed with different groups of metal ions: (1) Copper(II), iron(III), and nickel(II) yielded 0.8-4 nm spherical particles, similar to alpha-synuclein incubated without metal ions; (2) magnesium(II), cadmium(II), and zinc(II) gave larger, 5-8 nm spherical oligomers; and, (3) cobalt(II) and calcium(II) gave frequent annular oligomers, 70-90 nm in diameter with calcium(II) and 22-30 nm in diameter with cobalt(II). In the absence of metal ions, annular oligomers ranging 45-90 nm in diameter were observed after 10 d incubation, short branched structures appeared after a further 3 wk and extended filaments after 2-3 mo. Previous studies have shown that alpha-synuclein calcium binding is mediated by the acidic C terminus. We found that truncated alpha-synuclein (1-125), lacking the C-terminal 15 amino acids, did not form annular oligomers upon calcium addition, indicating the involvement of the calcium-binding domain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15537754      PMCID: PMC2287302          DOI: 10.1110/ps.04879704

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  62 in total

Review 1.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain.

Authors:  R A Crowther; S E Daniel; M Goedert
Journal:  Neurosci Lett       Date:  2000-10-06       Impact factor: 3.046

3.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.

Authors:  K A Conway; S J Lee; J C Rochet; T T Ding; R E Williamson; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

4.  Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.

Authors:  K A Conway; J D Harper; P T Lansbury
Journal:  Biochemistry       Date:  2000-03-14       Impact factor: 3.162

5.  Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons.

Authors:  D D Murphy; S M Rueter; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

6.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies.

Authors:  J M Souza; B I Giasson; Q Chen; V M Lee; H Ischiropoulos
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

7.  Nucleated conformational conversion and the replication of conformational information by a prion determinant.

Authors:  T R Serio; A G Cashikar; A S Kowal; G J Sawicki; J J Moslehi; L Serpell; M F Arnsdorf; S L Lindquist
Journal:  Science       Date:  2000-08-25       Impact factor: 47.728

8.  The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease.

Authors:  B C Campbell; C A McLean; J G Culvenor; W P Gai; P C Blumbergs; P Jäkälä; K Beyreuther; C L Masters; Q X Li
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

9.  Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments.

Authors:  P H Jensen; K Islam; J Kenney; M S Nielsen; J Power; W P Gai
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

10.  Conformational properties of alpha-synuclein in its free and lipid-associated states.

Authors:  D Eliezer; E Kutluay; R Bussell; G Browne
Journal:  J Mol Biol       Date:  2001-04-06       Impact factor: 5.469

View more
  55 in total

Review 1.  Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease.

Authors:  Seung-Jae Lee
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

Review 2.  Amyloidogenesis of natively unfolded proteins.

Authors:  Vladimir N Uversky
Journal:  Curr Alzheimer Res       Date:  2008-06       Impact factor: 3.498

3.  The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen.

Authors:  Jack T Rogers; Sohan Mikkilineni; Ippolita Cantuti-Castelvetri; Deborah H Smith; Xudong Huang; Sanghamitra Bandyopadhyay; Catherine M Cahill; Maria L Maccecchini; Debomoy K Lahiri; Nigel H Greig
Journal:  J Neural Transm (Vienna)       Date:  2011-01-08       Impact factor: 3.575

4.  Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions.

Authors:  Wenbo Zhou; Chunmei Long; Stephen H Reaney; Donato A Di Monte; Anthony L Fink; Vladimir N Uversky
Journal:  Biochim Biophys Acta       Date:  2009-12-21

5.  Polymer brain-nanotherapeutics for multipronged inhibition of microglial α-synuclein aggregation, activation, and neurotoxicity.

Authors:  Neal K Bennett; Rebecca Chmielowski; Dalia S Abdelhamid; Jonathan J Faig; Nicola Francis; Jean Baum; Zhiping P Pang; Kathryn E Uhrich; Prabhas V Moghe
Journal:  Biomaterials       Date:  2016-10-04       Impact factor: 12.479

Review 6.  Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs).

Authors:  Francois-Xavier Theillet; Andres Binolfi; Tamara Frembgen-Kesner; Karan Hingorani; Mohona Sarkar; Ciara Kyne; Conggang Li; Peter B Crowley; Lila Gierasch; Gary J Pielak; Adrian H Elcock; Anne Gershenson; Philipp Selenko
Journal:  Chem Rev       Date:  2014-06-05       Impact factor: 60.622

7.  Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes.

Authors:  Yong Peng; Chengshan Wang; Howard H Xu; You-Nian Liu; Feimeng Zhou
Journal:  J Inorg Biochem       Date:  2009-11-18       Impact factor: 4.155

8.  Potassium depolarization and raised calcium induces α-synuclein aggregates.

Authors:  Jordan Follett; Bonnie Darlow; Mathew B Wong; Jacob Goodwin; Dean L Pountney
Journal:  Neurotox Res       Date:  2012-12-19       Impact factor: 3.911

Review 9.  Exploring the accessible conformations of N-terminal acetylated α-synuclein.

Authors:  Gina M Moriarty; Maria K Janowska; Lijuan Kang; Jean Baum
Journal:  FEBS Lett       Date:  2013-03-13       Impact factor: 4.124

10.  Copper-triggered aggregation of ubiquitin.

Authors:  Fabio Arnesano; Simone Scintilla; Vincenza Calò; Elena Bonfrate; Chiara Ingrosso; Maurizio Losacco; Teresa Pellegrino; Enrico Rizzarelli; Giovanni Natile
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.